Results 121 to 130 of about 2,525 (153)

Broad spectrum of β-lactamase coverage and potent antimicrobial activity of xeruborbactam in combination with meropenem against carbapenemase-producing Enterobacterales, including strains resistant to new β-lactam/β-lactamase inhibitor combinations. [PDF]

Antimicrob Agents Chemother
Sánchez-Peña L, Rodríguez-Pallares S, Aja-Macaya P, Blanco-Martín T, González-Pinto L, Pérez-Rodríguez G, Le Terrier C, Portillo-Calderón I, Recacha E, Riazzo C, Vázquez-Ucha JC, Beceiro A, Aracil B, Oteo-Iglesias J, Martínez-Martínez L, Poirel L, Bou G, Arca-Suárez J.   +17 more
europepmc   +1 more source

Impact of the double deletion ΔG242-T243 in KPC-2 in the effectiveness of ceftazidime-avibactam and imipenem-relebactam. [PDF]

Antimicrob Agents Chemother
Brunetti F, Gutkind G, Gao L, Haider S, Bonomo RA, Power P.   +5 more
europepmc   +1 more source

<i>Achromobacter xylosoxidans</i> isolates exhibit genome diversity, variable virulence, high levels of antibiotic resistance, and potential intrahost evolution. [PDF]

mSphere
Acharya P, Lloyd C, Lam NT, Kumke J, Ray S, Yanira Muñoz Ramirez Z, Das S, Lam HN.   +7 more
europepmc   +1 more source

Genomic and molecular characterisation of a Klebsiella pneumoniae clinical isolate resistant to meropenem-vaborbactam, imipenem-relebactam, and ceftazidime-avibactam

Wan Y, Wong JLC, Sanchez-Garrido J, Low WW, Turton JF, Morecchiato F, Baccani I, Dodgson K, Rossolini GM, Woodford N, Frankel G, Jauneikaite E, Meunier D, Hopkins KL.   +13 more
europepmc   +1 more source